Market Overview

Bank Of America On AMD, Nvidia, And Intel's 'Processor-Gate'

Share:
Bank Of America On AMD, Nvidia, And Intel's 'Processor-Gate'
Related NVDA
Bank Earnings To The Rescue? Market Seeing Some Green After Strong Results
Investor Movement Index September Summary
Intel, AMD And Nvidia Are No Longer A Zero-Sum Game (Seeking Alpha)
Related AMD
How Millennials, Baby Boomers Are Reacting To Market Volatility
Macro News Motivates Investor Moves In September's IMX Report
Dow Jones Futures: 3 Reasons To Stay In Cash As Bulls, Bears Battle For Stock Market Control (Investor's Business Daily)

It’s been a volatile time for Intel Corporation (NASDAQ: INTC) and its key competitors Advanced Micro Devices, Inc. (NASDAQ: AMD) and NVIDIA Corporation (NASDAQ: NVDA) after Intel disclosed two large security issues in its chips. The fallout from the security issues will like continue to impact the market in the near-term, according to Bank of America Merrill Lynch. 

The Analyst

BofA analyst Vivek Arya maintains the following ratings and price targets for popular semiconductor stocks:

  • AMD: Buy rating, $18 price target.
  • Intel: Buy rating, $49 price target.
  • Nvidia: Buy rating, $251 price target.
  • The Thesis

    Investors should not sweat the cyclical peak in semiconductor demand that worries bears, Arya said in a Thursday note. (See the analyst's track record here.)

    Bank of America estimates that previous semiconductor cycles have lasted an average of 13 quarters, and said the current cycle is only in quarter seven.

    Semiconductor companies have a massive long-term opportunity in the industrial and automotive markets, Arya said. 

    “We believe this is an attractive set of well-managed 'new industrial' companies trading at underserved 15-20-percent discount (on EV/FCF metric) to S&P 500 industrials, despite 1.5x faster sales growth potential and despite 1000-bp-plus higher profit margins (36-percent average for this group vs S&P 500 industrials at 22-percent 2018E EBITDA margins)." 

    In the near-term, Arya said concerns over Spectre and Meltdown will weigh on Intel and AMD shares, at least until the companies update their 2018 guidance later this month.

    For Nvidia, the trifecta of artificial intelligence, gaming and autonomous vehicles gives the stock the most upside potential of the group, Arya said. Buyers should be aware that Nvidia currently trades at an elevated forward PE of around 42x, he said. 

    Price Action

    Despite the bullish commentary, Nvidia, AMD and Intel all traded lower on Friday. AMD was the laggard of the group, down 1.7 percent in midday trading.

    Related Links:

    Nvidia, AMD Among Top Semis In 2018, According To Bank Of America

    Intel's Potentially Major Security Flaw Boosting AMD, Other Chip Stocks 

Latest Ratings for NVDA

DateFirmActionFromTo
Sep 2018KeyBancInitiates Coverage OnSector Weight
Aug 2018OppenheimerUpgradesPerformOutperform
Aug 2018Stifel NicolausMaintainsHoldHold

View More Analyst Ratings for NVDA
View the Latest Analyst Ratings

Posted-In: Analyst Color Long Ideas Price Target Reiteration Top Stories Analyst Ratings Tech Trading Ideas Best of Benzinga

 

Related Articles (INTC + AMD)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
NFLXKeyBancDowngrades0.0
DLTRKeyBancMaintains108.0
LRCXKeyBancMaintains231.0
AKRXPiperJaffrayUpgrades9.0
ANETBMO CapitalUpgrades279.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Concert Pharma Drops On Patent Litigation Setback; Mizuho Downgrades

Miragen Could Surpass $1 Billion In Revenue In 2025, Says Biotech Analyst